The "Usher Syndrome - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.
The report provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.
Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Amgen Inc Clearside BioMedical Inc Editas Medicine Inc Eloxx Pharmaceuticals Inc Ionis Pharmaceuticals Inc Odylia Therapeutics Inc ProQR Therapeutics NV Wave Life Sciences Ltd
The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders). The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction Report Coverage Usher Syndrome - Overview Usher Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Usher Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Usher Syndrome - Companies Involved in Therapeutics Development Usher Syndrome - Drug Profiles Mechanism Of Action R&D Progress Usher Syndrome - Dormant Projects Usher Syndrome - Discontinued Products Usher Syndrome - Product Development Milestones Featured News & Press Releases May 02, 2019: Eloxx Pharmaceuticals presents positive new data at the Association for Research in Vision and Ophthalmology "ARVO" 2019 Annual Meeting Jul 05, 2017: ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA May 01, 2017: ProQR to Present Data on QRX-411 at ARVO Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Disclaimer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qk0cy9
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005376/en/
SOURCE: Research and Markets
ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900